CAR T cell therapy cancer treatment face-off
It's a type of cancer immunotherapy, or a therapy that harness the body's immune system to take on cancer cells. Short for chimeric antigen receptor T-cell therapy, CAR-T treatment takes a person's own cells, removes them from the body, re-engineers them, and then puts the cells back in the body where they can attack cancer cells. That's for Kite's CAR-T treatment for aggressive B-cell non-Hodgkin lymphoma (more general than DLBCL). And in July 2016, another CAR-T company, Juno Therapeutics, said four people in its clinical trials had died, all from cerebral edema. In May, Kite Pharma revealed that one person had died in a clinical trial for its late-stage CAR-T therapy from cerebral edema, a condition in which excessive fluid causes the brain to swell.Focus on T-cell therapyOne approach is the so-called adoptive T-cell therapy, which involves removing immune cells from the body and genetically arming them. "If that step succeeds, the approach would enlarge the arsenal of T-cells suitable for adoptive T-cell therapy," Elfriede Nößner states. "But there are ways to support the immune system in recognizing and combating cancer cells." Scientists are working to find new treatment possibilities, and have been concentrating on the body's own immune system for some time. She and her team were therefore searching for a different way to improve the defense provided by the immune cells.
collected by :Lucy William
No comments:
Post a Comment